2020
DOI: 10.1016/j.radonc.2020.01.025
|View full text |Cite
|
Sign up to set email alerts
|

Pattern of relapse and dosimetric analysis of a single dose 19 Gy HDR-brachytherapy phase II trial

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

1
5
0

Year Published

2021
2021
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 13 publications
(6 citation statements)
references
References 17 publications
1
5
0
Order By: Relevance
“…As already reported in other series, in the SiFEPI trial local relapse occurred in or close to the initial anatomical site [12] , [13] , [15] , [17] . However, no significant difference in terms of dosimetric data were observed between patients with and without local relapse ( e-Table 2 and 3 and e-Fig.…”
Section: Discussionsupporting
confidence: 78%
See 2 more Smart Citations
“…As already reported in other series, in the SiFEPI trial local relapse occurred in or close to the initial anatomical site [12] , [13] , [15] , [17] . However, no significant difference in terms of dosimetric data were observed between patients with and without local relapse ( e-Table 2 and 3 and e-Fig.…”
Section: Discussionsupporting
confidence: 78%
“…The second hypothesis (possibly combined with the first one) is a potential “geographic miss” of ITPL. Such unacceptable biochemical results may be explained in part by the dose–response relationship as proposed by Gomez-Ituriaga et al [13] , while patients treated with cooler implants have a higher incidence of local failure. Indeed, in this study, on multivariate analysis, with a single fraction of 19 Gy, a V100 < 96 % appears an independent predictor of biochemical failure.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…In 2014, a phase II trial evaluating the safety and feasibility of HDR-BT 19 Gy for low- and intermediate-risk localized prostate cancer was initiated in our radiation oncology department. After a median follow-up of 48 months, 32% of patients developed a biochemical failure [ 7 ].…”
Section: Methodsmentioning
confidence: 99%
“…Several studies have demonstrated favorable toxicity rates and excellent results in the impact on quality of life after 19 Gy single-fraction high-dose-rate brachytherapy (HDR-BT 19 Gy) [ 1 , 2 , 3 , 4 , 5 ]. However, in the last few years, some trials have reported higher biochemical and local failure rates than expected with this dose schedule [ 5 , 6 , 7 , 8 , 9 ].…”
Section: Purposementioning
confidence: 99%